US 12,214,032 B2
Porcine Reproductive and Respiratory Syndrome vaccine virus
Stephen Qitu Wu, Fishers, IN (US); Cinta Prieto Suarez, Madrid (ES); and Geoffrey Gregory Labarque, Neuilly sur Seine (FR)
Assigned to Elanco UK AH Limited, Hampshire (GB); and Elanco US Inc, Greenfield, IN (US)
Appl. No. 17/618,625
Filed by Elanco US, Inc., Greenfield, IN (US); and Elanco UK AH Limited, Hampshire (GB)
PCT Filed Sep. 27, 2019, PCT No. PCT/EP2019/076174
§ 371(c)(1), (2) Date Dec. 13, 2021,
PCT Pub. No. WO2021/037387, PCT Pub. Date Mar. 4, 2021.
Claims priority of application No. 19382734 (EP), filed on Aug. 29, 2019.
Prior Publication US 2022/0241393 A1, Aug. 4, 2022
Int. Cl. A61K 39/12 (2006.01); A61P 31/14 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61P 31/14 (2018.01); C12N 7/00 (2013.01); A61K 2039/525 (2013.01); A61K 2039/552 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A modified, live Porcine Reproductive and Respiratory Syndrome (PRRS) virus strain, wherein the consensus complementary DNA sequence of said PRRS strain is at least 95% identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4.